Molecular structure of Dabigatran, CAS Number: 211914-51-1
Dabigatran (CAS 211914-51-1)
See product citations (1)
Alternate Names:
Pradaxa; BIBR 953
Application:
Dabigatran is A highly selective, reversible, and potent thrombin inhibitor
CAS Number:
211914-51-1
Molecular Weight:
471.51
Molecular Formula:
C25H25N7O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dabigatran, a direct thrombin inhibitor. As a synthetic, reversible, and direct thrombin inhibitor, this small molecule exhibits remarkable selectivity for thrombin, exhibiting a rapid onset and offset of action. Additionally, Dabigatran acts as a substrate for cytochrome P450 enzymes. By binding to the active site of thrombin, Dabigatran effectively impedes its interaction with fibrinogen, hindering fibrin formation— an integral process in clotting.
Dabigatran (CAS 211914-51-1) References
- Enhanced elimination of dabigatran through extracorporeal methods. | Awad, NI., et al. 2015. J Med Toxicol. 11: 85-95. PMID: 25448250
- Dabigatran for the treatment of venous thromboembolism. | Schellong, SM. 2015. Expert Rev Hematol. 8: 413-25. PMID: 26111881
- Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. | Grottke, O., et al. 2016. Crit Care. 20: 115. PMID: 27125504
- Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. | Antonijevic, NM., et al. 2017. Curr Drug Metab. 18: 622-635. PMID: 28460624
- Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. | Giustozzi, M., et al. 2017. J Thromb Thrombolysis. 44: 527-535. PMID: 28913672
- Dabigatran must be used carefully: literature review and recommendations for management of adverse events. | Lin, S., et al. 2019. Drug Des Devel Ther. 13: 1527-1533. PMID: 31190734
- Dabigatran-induced esophagitis masking esophageal cancer. | Iwamuro, M., et al. 2021. Dig Liver Dis. 53: 251-252. PMID: 32505570
- Real-world experience with reversal of dabigatran by idarucizumab. | Haastrup, SB., et al. 2021. Thromb Res. 197: 179-184. PMID: 33227654
- Impact of Dabigatran Treatment on Rotation Thromboelastometry. | Sokol, J., et al. 2021. Clin Appl Thromb Hemost. 27: 1076029620983902. PMID: 33523711
- Dabigatran: its protective effect against endothelial cell damage by oxysterol. | Gorzelak-Pabiś, P., et al. 2022. Biomed Pharmacother. 147: 112679. PMID: 35121342
- A systematic review and meta-analysis of dabigatran peak and trough concentration in adults. | Ng, JW., et al. 2022. Br J Clin Pharmacol. 88: 4443-4459. PMID: 35665523
- Intravenous Dabigatran Provides Adequate Anticoagulation for Cardiopulmonary Bypass Using a Rabbit Model. | Nadtochiy, SM., et al. 2023. Anesthesiology. 138: 523-532. PMID: 36821759
Inhibitor of:
BPNT1, C4b, CD42d, DIC, Factor IX, Factor V, Factor VII, Factor VIII, Factor XIII A, Fibrinogen β, HABP2, Hirudin, HPRG, HRG-α, NCAG1, Olr415, PN-1, Protein Z, PT, TFPI, TFPI-2, Thrombin, Thrombin R, and VKORC1.Activator of:
APMSF, C1INH, HCII, Hirudin, Kininogen, PARP-4, PEPT1, Protein C, RPESP, SERPINE3, and TLCK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dabigatran, 5 mg | sc-481166 | 5 mg | $205.00 |